Monovalent binding proteins

• US 9,856,319 B2
• Filed: 12/27/2013
• Issued: 01/02/2018
• Est. Priority Date: 12/28/2012
• Status: Active Grant

• Current Assignee: Abbvie Incorporated
• Original Assignee: Abbvie Incorporated
• Inventors: Ghayur, Tariq, Gu, Jijie
• Primary Examiner(s): DUFFY, BRADLEY
• Application Number:
  US14/141,503
• Publication Number:
  US 20140221622A1
• Time in Patent Office: 1,467 Days
• Field of Search: None
• CPC Class Codes: C07K 16/2809 against the T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 16/2863 against receptors for growth factors, growth regulators
• CPC Class Codes: C07K 16/2878 against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 16/32 against translation products of oncogenes
• CPC Class Codes: C07K 16/468 Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
• CPC Class Codes: C07K 2317/35 Valency
• CPC Class Codes: C07K 2317/55 Fab or Fab'
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/74 Inducing cell proliferation
• CPC Class Codes: C07K 2317/75 Agonist effect on antigen
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2317/94 Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

Claims

1. A monovalent, monospecific binding protein comprising at least two variable heavy domains, at least two variable light domains, and four polypeptide chains, wherein two of said four polypeptide chains comprise VDH-(X1)n-C—

(X2)n, wherein

VDH is a heavy chain variable domain,

X1 is a linker with the proviso that it is not CH1,

C is a heavy chain constant domain,

X2 is an Fc region,

n is 0 or 1;

and

wherein two of said four polypeptide chains comprise VDL-(X3)n-C—

(X4)n, wherein

VDL is a light chain variable domain,

X3 is a linker with the proviso that it is not CH1,

C is a light chain constant domain,

X4 does not comprise an Fc region;

n is 0 or 1;

wherein one of said at least two heavy chain variable domains and/or one of said at least two light chain variable domains comprises a non-naturally occurring mutation, wherein said mutation inhibits targeted binding between a specific antigen and—

a mutant binding domain formed by the variable domain comprising the mutation.

2. The binding protein of claim 1, wherein the Fc region of the two polypeptide chains having a formula of VDH-(X1)n-C—

(X2)n each comprises a mutation, wherein said mutations on the two Fc regions enhance heterodimerization of the two polypeptide chains.

3. The binding protein of claim 1, wherein one of the four polypeptide chains has a sequence identical to a polypeptide chain selected from the group consisting of SEQ ID Nos. 13-18.

4. The binding protein of claim 1 wherein the mutation combination in antigen binding domain can be acquired by a random-mutagenesis library approach and screened by a functional assay, or can be acquired by a crystallization or molecular modeling-guided approach.

5. A binding protein conjugate comprising a binding protein of claim 1, wherein the binding protein conjugate further comprises an agent selected from the group consisting of an immunoadhesion molecule, an imaging agent, a therapeutic agent, and a cytotoxic agent.

6. A pharmaceutical composition comprising the binding protein of claim 1, and a pharmaceutically acceptable carrier.

7. The pharmaceutical composition of claim 6, further comprising at least one additional agent for treating a disorder, wherein the at least one additional agent is selected from the group consisting of a therapeutic agent, an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional fragment thereof, methotrexate, cyclosporin, rapamycin, FK506, a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteriod, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.